352 related articles for article (PubMed ID: 21960560)
1. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach.
Schmitz S; Adams R; Walsh CD; Barry M; FitzGerald O
Ann Rheum Dis; 2012 Feb; 71(2):225-30. PubMed ID: 21960560
[TBL] [Abstract][Full Text] [Related]
2. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.
Alonso-Ruiz A; Pijoan JI; Ansuategui E; Urkaregi A; Calabozo M; Quintana A
BMC Musculoskelet Disord; 2008 Apr; 9():52. PubMed ID: 18419803
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of biological agents in methotrexate-refractory rheumatoid arthritis patients: a Bayesian mixed treatment comparison.
Choi M; Hyun MK; Choi S; Tchoe HJ; Lee SY; Son KM; Kim MJ; Jung YO; Kim HA
Korean J Intern Med; 2017 May; 32(3):536-547. PubMed ID: 27253239
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.
Nixon R; Bansback N; Brennan A
Rheumatology (Oxford); 2007 Jul; 46(7):1140-7. PubMed ID: 17478472
[TBL] [Abstract][Full Text] [Related]
6. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom.
Guyot P; Taylor PC; Christensen R; Pericleous L; Drost P; Eijgelshoven I; Bergman G; Lebmeier M
J Rheumatol; 2012 Jun; 39(6):1198-206. PubMed ID: 22505698
[TBL] [Abstract][Full Text] [Related]
7. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis.
Guyot P; Taylor P; Christensen R; Pericleous L; Poncet C; Lebmeier M; Drost P; Bergman G
Arthritis Res Ther; 2011; 13(6):R204. PubMed ID: 22151924
[TBL] [Abstract][Full Text] [Related]
8. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis.
Hochberg MC; Tracy JK; Hawkins-Holt M; Flores RH
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii13-6. PubMed ID: 14532140
[TBL] [Abstract][Full Text] [Related]
10. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis.
Launois R; Avouac B; Berenbaum F; Blin O; Bru I; Fautrel B; Joubert JM; Sibilia J; Combe B
J Rheumatol; 2011 May; 38(5):835-45. PubMed ID: 21239748
[TBL] [Abstract][Full Text] [Related]
11. Indirect comparison of biological treatments in refractory rheumatoid arthritis.
Gallego-Galisteo M; Villa-Rubio A; Alegre-del Rey E; Márquez-Fernández E; Ramos-Báez JJ
J Clin Pharm Ther; 2012 Jun; 37(3):301-7. PubMed ID: 21831256
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
13. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
Mary J; De Bandt M; Lukas C; Morel J; Combe B
J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
[TBL] [Abstract][Full Text] [Related]
14. Golimumab for the treatment of psoriatic arthritis.
Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
[TBL] [Abstract][Full Text] [Related]
15. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.
Kristensen LE; Christensen R; Bliddal H; Geborek P; Danneskiold-Samsøe B; Saxne T
Scand J Rheumatol; 2007; 36(6):411-7. PubMed ID: 18092260
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis.
Rau R
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S58-64. PubMed ID: 21044435
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice.
Kievit W; Fransen J; Oerlemans AJ; Kuper HH; van der Laar MA; de Rooij DJ; De Gendt CM; Ronday KH; Jansen TL; van Oijen PC; Brus HL; Adang EM; van Riel PL
Ann Rheum Dis; 2007 Nov; 66(11):1473-8. PubMed ID: 17426065
[TBL] [Abstract][Full Text] [Related]
18. The Challenge of Treating Early-Stage Rheumatoid Arthritis: The Contribution of Mixed Treatment Comparison to Choosing Appropriate Biologic Agents.
Migliore A; Bizzi E; Petrella L; Bruzzese V; Cassol M; Integlia D
BioDrugs; 2016 Apr; 30(2):105-15. PubMed ID: 26905069
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
Punzi L; Lapadula G; Mathieu A
BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
Soini EJ; Hallinen TA; Puolakka K; Vihervaara V; Kauppi MJ
J Med Econ; 2012; 15(2):340-51. PubMed ID: 22168785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]